Strong Performance Leads to Upgraded Guidance: CEO Sells $1.5 Million in Shares Amid AI Investments

Labcorp Holdings Inc. (NYSE: LH) reported first-quarter 2026 revenue of $3.54 billion, up 5.8% year over year, and diluted EPS of $3.35, a more than 30% increase. In light of these strong results, the company raised its full-year guidance for both revenue growth and adjusted EPS.

Management also highlighted progress on key strategic initiatives: new and expanded collaborations with Philadelphia Children’s Hospital, Illumina, PathAI, Optum.ai and AWS/Datavant; growth in specialty and companion diagnostics as well as consumer testing; and the upcoming May launch of its AI-driven MyLabcorp consumer app.

During the quarter, Labcorp balanced shareholder returns with growth through acquisitions, share repurchases and dividends. It declared a quarterly dividend of $0.72 per share payable June 11 to shareholders of record as of May 29.

Separately, on May 11, President and CEO Adam H. Schechter sold approximately 5,900 shares at $254.50 each under a prearranged trading plan, generating $1.5 million in proceeds. He continues to hold roughly $27.4 million worth of Labcorp stock.

Labcorp has been broadening its oncology and pediatric diagnostics portfolio. It recently received FDA approval for a companion diagnostic to identify ovarian cancer patients eligible for Keytruda immunotherapy, and announced a partnership with Philadelphia Children’s Hospital to expand access to advanced pediatric testing nationwide.

Headquartered in North Carolina, Labcorp is a global life-sciences and diagnostics company. Through its diagnostics and biopharma research-support businesses, it conducts hundreds of millions of tests annually in over 100 countries and supports numerous drug-development programs.

The U.S. clinical-laboratory market is dominated by a few large players, including Labcorp and Quest Diagnostics, and continues to grow over the medium to long term, driven by an aging population, rising chronic-disease prevalence, cost-efficiency demands and the spread of AI and genomic-analysis technologies.